Mohamed Gouda, Clinical Fellow at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by him and colleagues published in Journal of Immunotherapy and Precision Oncology:
“Now published in JIPO: Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma.
And interview with Dr. Sapna Patel about the study’s highlights.”
Authors: Mohamed Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna Patel.
More posts featuring Mohamed Gouda.